{
    "organizations": [],
    "uuid": "f35a2a1167caee638894c909a0d8e361e8423fab",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-miragen-announces-interim-data-fro/brief-miragen-announces-interim-data-from-phase-1-trial-of-cobomarsen-in-mycosis-fungoides-idUSASC0A0MU",
    "ord_in_thread": 0,
    "title": "BRIEF-Miragen Announces Interim Data From Phase 1 Trial Of Cobomarsen In Mycosis Fungoides",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 8 (Reuters) - miRagen Therapeutics Inc:\n* MIRAGEN THERAPEUTICS ANNOUNCES NEW INTERIM DATA FROM PHASE 1 CLINICAL TRIAL OF COBOMARSEN IN MYCOSIS FUNGOIDES\n* MIRAGEN THERAPEUTICS INC - COBOMARSEN CONTINUED TO BE GENERALLY WELL TOLERATED AT ALL DOSE LEVELS EVALUATED\n* MIRAGEN THERAPEUTICS ANNOUNCES NEW INTERIM DATA FROM PHASE 1 CLINICAL TRIAL OF COBOMARSEN IN MYCOSIS FUNGOIDES Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-09T06:46:00.000+03:00",
    "crawled": "2018-05-09T12:33:19.020+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "miragen",
        "therapeutic",
        "inc",
        "miragen",
        "therapeutic",
        "announces",
        "new",
        "interim",
        "data",
        "phase",
        "clinical",
        "trial",
        "cobomarsen",
        "mycosis",
        "fungoides",
        "miragen",
        "therapeutic",
        "inc",
        "cobomarsen",
        "continued",
        "generally",
        "well",
        "tolerated",
        "dose",
        "level",
        "evaluated",
        "miragen",
        "therapeutic",
        "announces",
        "new",
        "interim",
        "data",
        "phase",
        "clinical",
        "trial",
        "cobomarsen",
        "mycosis",
        "fungoides",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}